AI assistant
PULSE BIOSCIENCES, INC. — Director's Dealing 2025
Jan 14, 2025
32093_dirs_2025-01-13_5dfdeb8a-9847-4d25-ac0d-d43f815e73bf.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: PULSE BIOSCIENCES, INC. (PLSE)
CIK: 0001625101
Period of Report: 2025-01-09
Reporting Person: LAVIOLETTE PAUL A (Director, Chief Executive Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-01-09 | Stock Option (right to buy) | $18.43 | A | 450000 | Acquired | 2035-01-09 | Common Stock (450000) | Direct |
| 2025-01-09 | Stock Option (right to buy) | $18.43 | A | 1050000 | Acquired | 2035-01-09 | Common Stock (1050000) | Direct |
Footnotes
F1: One-fourth of the shares subject to the option will vest on the three-year anniversary of the grant and the remaining shares will vest on the four-year anniversary of the grant, subject to the Reporting Person's continued service through each vesting date.
F2: The shares subject to this option are subject to five tranches of performance-based vesting criteria tied to certain operating targets and the Issuer's market capitalization ranging from $3 billion to $9 billion, in all cases, subject to the Reporting Person's continued service through each vesting milestone.